Pharmtech & Ingredients 2019 will start its work in two weeks
Don’t miss out on the exciting opportunities at the 21st international exhibition of equipment, raw materials and technologies for pharmaceutical production – Pharmtech & Ingredients 2019. It’s the largest event of its kind in Russia, bringing together the entire pharmaceutical industry under one roof. If you’re looking for new equipment, new suppliers, or to stay up-to-date on the latest industry trends, you need to be at Pharmtech & Ingredients 2019 this November.
Manufacturers and suppliers from Germany, Switzerland, India and China will showcase their brands within group stands. The number of Chinese companies offering the Russian market raw materials and ingredients for pharmaceutical production has doubled this year, which was a product sector of interest to 39% of visitors last year.
The exhibition’s agenda of events will kick off on day 1 with a round table discussion on the readiness of the industry for labelling as part of Russia’s Seven Nosologies Programme.
Also taking place that day is the round table discussion ‘Export potential: new growth points’, which is a hot topic within the pharmaceutical industry at the moment as more and more companies look to export their pharmaceutical products.
20 November will see the discussion session ‘An effective look at the technical support for medicine production’, which will pay particular attention to innovative solutions to improve performance indicators at different stages of production.
The topic of Active Pharmaceutical Ingredients (APIs) will be covered extensively at the round table discussion ‘API production, the economic aspect’ on 20 November, which will look into how the resolution regulating public procurement of medicines will work and what economic effect it may have.
A first for Russia, the Pharmtechprom forum will see BASF present a scientific system for predicting formulations to help create technologically advanced medicines. The digital assistant will simplify and reduce the cost of the medicine development process, as well as minimise the risk of disruption.
Back to the list